Campbell N P, Pantridge J F, Adgey A A
Br Heart J. 1978 Jul;40(7):796-801. doi: 10.1136/hrt.40.7.796.
Forty-eight patients with ischaemic heart disease received oral mexiletine for the control or prevention of ventricular arrhythmias. The most frequently used doses were 200, 250, and 300 mg 8-hourly. The treatment period varied from 2 days to more than 1 year (median 3 months). No ventricular arrhythmias were detected in more than one-half of the patients. Severe side effects occurred in 15 (31%) of the 48 patients. Major ventricular arrhythmias were observed in 14 (29%) of the 48 patients at a time when the majority had plasma concentrations within the therapeutic range. The value of mexiletine in the management of patients at risk of sudden death is likely to be limited.
48例缺血性心脏病患者口服美西律以控制或预防室性心律失常。最常用剂量为每8小时200、250和300毫克。治疗期从2天到1年以上不等（中位数为3个月）。超过一半的患者未检测到室性心律失常。48例患者中有15例（31%）出现严重副作用。48例患者中有14例（29%）在大多数患者血浆浓度处于治疗范围内时观察到严重室性心律失常。美西律在管理有猝死风险的患者中的价值可能有限。
